PharmaCyte Biotech, Inc. plans to develop a diabetes treatment using its Cell-in-a-Box® platform technology. In 2013, the company acquired the exclusive worldwide rights to the cellulose-based-live-cell encapsulation technology usage, becoming well positioned to develop treatments for diabetes. Presently, PharmaCyte Biotech has advanced in its development of a line of “live cells” that could be encapsulated in the Cell-in-a-Box technology and ultimately used as a bio-artificial pancreas.
Read the complete article published recently in the Diabetes News Journal.
